目的 分析2012—2016年天津市胸科医院调血脂药物的使用情况及用药趋势，促进其合理应用。方法 对2012—2016年天津市胸科医院调血脂药物的销售金额、用药频度（DDDs）、限定日费用（DDC）等进行统计分析。结果 2012—2016年，调血脂药物的销售金额、占西药销售金额的比例总体上呈上升趋势，但销售占比在2016年有所下降；各类调脂药物的销售情况分析显示，除烟酸类调血脂药物外，其余均呈上升趋势；阿托伐他汀的DDDs最高，瑞舒伐他汀的DDDs增幅最大；他汀类等一线的调血脂药物的销售金额及比例始终居于首位，同时其DDC呈下降趋势。结论 2012—2016年天津市胸科医院调血脂药物的使用基本合理，经过价格的调整，患者的经济负担减轻。

Objective To analyze the situation and developing trend of regulating blood-lipid drugs in Tianjin Thoracic Hospital from 2012 to 2016, and to promote the reasonable application. Methods Consumption sum, frequency of drug use (DDDs), and defined daily cost (DDC) of regulating blood-lipid drugs in Tianjin Thoracic Hospital from 2012 to 2016 were analyzed.Results From 2012 to 2016, consumption sum and the ratio of regulating blood-lipid drugs in Western medicine sales were overall on the rise, but the sales proportion declined in 2016. Sales of all kinds of regulating blood-lipid drugs revealed that besides nicotinic acid regulating blood-lipid drugs, the rest had the rising trend. DDDs of atorvastatin was the highest, and DDDs amplification of rosuvastatin was the largest. Consumption sum and proportion of statin regulating blood-lipid drugs were always in the first place, and at the same time DDC was on the decline. Conclusion The utilization of regulating blood-lipid drugs in Tianjin Thoracic Hospital from 2012 to 2016 is rational on the whole. Through adjusting the prices, the financial burden of patients is reduced.